Chemical scan

History

2024: Establishing a Company

The pharmaceutical company ChemRar and the network of private clinics Medskan have joined forces to expand their presence on the international drug market. In mid-August 2024, it became known about the creation of the Khimskan joint venture, which will be engaged in the research and promotion of drugs in Russia and friendly countries.

According to Kommersant, the new company is registered on a parity basis by the ChemRara structure of IIHR LLC and Medskan JSC. Denis Vinokurov, who previously held the position of Director for International Development of KhimRara, has been appointed General Director of Khimskan.

Freepik

The main focus of the joint venture is the unification of research and commercial competencies for work in the markets of Russia and foreign countries. The countries of the Middle East, Africa, Southeast Asia and Latin America were chosen as priority areas.

At the initial stage, Khimskan will focus on promoting drugs from the existing portfolio of KhimRara. It includes generics of cancer and ARV drugs, as well as the company's own developments - Elpida for the treatment of HIV and Aviandra, used in generalized anxiety disorder.

Medskan, half of which belongs to the Rosatom division of Rosatom Health Technologies, acts as a center for medical competencies and a commercial division of the state corporation. Such a partnership can provide KhimRar with access to new international markets, given the wide geography of Rosatom's presence in more than 50 countries of the world.

The creation of Khimskan is taking place against the background of a general decline in the export of Russian drugs. In 2023, the volume of supplies decreased by 23% to $0.99 billion. However, a number of domestic producers declare plans to increase exports. Thus, Pharmasintez intends to increase foreign supplies by 5-10 times in the next two years.^[1]

Notes